The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Paliperidone for schizophrenia
Abstract
PURPOSE: The efficacy, safety, pharmacology, pharmacokinetics, drug-drug interactions, and administration of paliperidone for schizophrenia are reviewed. SUMMARY: Paliperidone is a benzisoxazole derivative and the principal active metabolite of risperidone. Representative of most oxidative metabolites, paliperidone is less lipophilic than risperidone. Like other atypical antipsychotics, paliperidone has a greater affinity for serotonin type 2A- receptor blockade relative to dopamine type 2-receptor blockade. Paliperidone's advanced-generation osmotic release delivery system allows for the avoidance of dosage adjustment when initiating therapy and may decrease the frequency of antido-paminergic effects that would occur with an immediate-release formulation. The pharmacologic actions of paliperidone are similar to other high potency atypical antipsychotics. The receptor-binding profile of paliperidone most closely resembles that of risperidone and ziprasidone. Paliperidone differs from risperidone and most other antipsychotics by its relatively low extent of enzymatic metabolism. A limited number of investigations have demonstrated the ability of paliperidone to produce significant improvements in psychopathology, functioning, and relapse in patients with schizophrenia when compared with placebo. Paliperidone appears to have a similar adverse-effect profile compared to risperidone, except for an increased rate of hyperprolactinemia. The recommended dose of paliperidone for the treatment of adults with schizophrenia is 6 mg every morning. CONCLUSION: Paliperidone does not offer any clear advantage over other atypical antipsychotics with a similar receptor-binding profile, such as risperidone and ziprasidone. Nevertheless, a few investigations have demonstrated the ability of paliperidone to produce significant improvements in psychopathology, functioning, and relapse when compared with placebo. Based on limited studies, the frequency of adverse effects, except for hyperprolactinemia, appears to favor paliperidone over risperidone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383
Self-citationMorosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · PubMed · Cited by 1,168
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101004323.x · Cited by 1,097
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Kapur, S., Zipursky, R. B., & Remington, G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 712
The Economic Burden of Schizophrenia in the United States in 2002
Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614
Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 469
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Gender differences in the epidemiology and treatment of anxiety disorders.
Pigott, T. A. (1999) · PubMed · Cited by 350
Receptor pharmacology of neuroleptics: relation to clinical effects.
Richelson, E. (1999) · PubMed · Cited by 306
Targeting the dopamine D2receptor in schizophrenia
Seeman, P. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.515 · Cited by 302
KANE, J., CANAS, F., KRAMER, M., FORD, L., GASSMANNMAYER, C., LIM, P., & EERDEKENS, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.012 · Cited by 296
Absorption, metabolism, and excretion of risperidone in humans.
Mannens, G., Huang, M. L., Meuldermans, W., Hendrickx, J., Woestenborghs, R., & Heykants, J. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08211-x · Cited by 261
Davidson, M., Emsley, R., Kramer, M., Ford, L., Pan, G., Lim, P., & Eerdekens, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.003 · Cited by 249
Valenstein, M., Ganoczy, D., McCarthy, J. F., Kim, H. M., Lee, T. A., & Blow, F. C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1008 · Cited by 238
Kramer, M., Simpson, G., Maciulis, V., Kushner, S., Vijapurkar, U., Lim, P., & Eerdekens, M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802dda4a · Cited by 224
Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review
Murphy, B. P., Chung, Y.-C., Park, T.-W., & McGorry, P. D. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.002 · Cited by 217
Goodwin, F. K. (2003) · PubMed · Cited by 209
Negative symptoms of schizophrenia: a problem that will not go away
Stahl, S. M., & Buckley, P. F. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00947.x · Cited by 195
Impact of Substance Use Disorder on ADHD and Its Treatment
Wilens, T. E., & Upadhyaya, H. P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0807e20 · Cited by 188
Conley, R., Gupta, S. K., & Sathyan, G. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132613 · Cited by 186
EPS Profiles: The Atypical Antipsychotics
Weiden, P. J. (2007) · Journal of Psychiatric Practice · doi:10.1097/00131746-200701000-00003 · Cited by 177
van Beijsterveldt, L. E. C., Geerts, R. J. F., Leysen, J. E., Megens, A. A. H. P., Van den Eynde, H. M. J., Meuldermans, W. E. G., & Heykants, J. J. P. (1994) · Psychopharmacology · doi:10.1007/bf02245444 · Cited by 177
Stahl, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0102 · Cited by 153
Predominant Role of the 9-Hydroxy Metabolite of Risperidone in Elevating Blood Prolactin Levels
Knegtering, R., Baselmans, P., Castelein, S., Bosker, F. J., Bruggeman, R., & van den Bosch, R. J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.1010 · Cited by 150
Shin, J., Soukhova, N. V., & Flockhart, D. A. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15029-5 · Cited by 143
Spina, E., Avenoso, A., Facciolà, G., Salemi, M., Scordo, M. G., Giacobello, T., Madia, A. G., & Perucca, E. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200008000-00019 · Cited by 132
Spina, E., Avenoso, A., Scordo, M. G., Ancione, M., Madia, A. G., Gatti, G., & Perucca, E. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00014 · Cited by 129
A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone
Remington, G. J., Mamo, D. C., Labelle, A., Reiss, J. P., Shammi, C., Mannaert, E., Mann, S. W., & Kapur, S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.396 · Cited by 125
Spina, E., Avenoso, A., Facciolà, G., Scordo, M. G., Ancione, M., & Madia, A. G. (2001) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200106000-00007 · Cited by 109
Plasma protein binding of risperidone and its distribution in blood
Mannens, G., Meuldermans, W., Snoeck, E., & Heykants, J. (1994) · Psychopharmacology · doi:10.1007/bf02244986 · Cited by 101
Mechanic, D. (2007) · PubMed · Cited by 80
Reist, C., Mintz, J., Albers, L. J., Jamal, M. M., Szabó, S., & Özdemir, V. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e5126 · Cited by 63
JUNG, S., Kim, K., CHO, H., JUNG, I., Park, P., BYUN, W., & Park, J. Y. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.007 · Cited by 58
Turner, M. S., & Stewart, D. W. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806071243 · Cited by 47
Lieberman, J. A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0207e05 · Cited by 46
Dose-Dependent Interaction of Paroxetine With Risperidone in Schizophrenic Patients
Saito, M., Yasui‐Furukori, N., Nakagami, T., Furukori, H., & Kaneko, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000185428.02430.c7 · Cited by 40
Percudani, M., Barbui, C., & Tansella, M. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422110-00002 · Cited by 40
Nasrallah, H. A. (2007) · PubMed · Cited by 34
Cited by
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Metadata
- Authors
- Dolder, C., Nelson, M., & Deyo, Z.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-01
- Volume
- 65
- Issue
- 5
- Pages
- 403-413
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2016880063
- Cited by
- 254
- References
- 43
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.